Transactions
11
Insider / LIGAND PHARMACEUTICALS INC
Haas Jason
Director at LIGAND PHARMACEUTICALS INC
- Company
- LIGAND PHARMACEUTICALS INC
- Ticker
- LGND
- First filing on record
- June 9, 2026
- Latest trade on record
- August 12, 2026
- SEC filings
- EDGAR ↗
Haas Jason, Director at LIGAND PHARMACEUTICALS INC, has disclosed 11 transactions in LGND since June 9, 2026: 0 purchases (0 open-market buys) and 3 sales, worth about $4.3M at the reported prices. The latest was filed August 14, 2026, 2 days after the trade.
Open-market buys
0
Sales
3
Avg. disclosure lag
2.9d
Trading in charts
Trade timeline
When does this person trade, how big, and in which direction? Every trade in the last 12 months.
Bought (above the line)Sold (below the line)Other transaction
In the last 12 months Haas Jason made no purchases and 3 sales worth $3.7M, plus 8 other transactions. Dot size is the dollar amount.
Portfolio mix
Which stocks does this person trade most? Tile size is dollars traded, all time on record.
Haas Jason has traded 1 stock on record; the largest by dollars is LGND.
Reporting lag
Does this person report on time? One bar per filing against the Form 4 deadline.
On timeLate
0 of 3 filings on record were reported after the Form 4 deadline (two business days, counted here as 4 calendar days).
What kind of transactions
Most Form 4 rows are pay arriving or tax being withheld, not a decision to buy or sell. Only code P is an open-market purchase and code S an open-market sale. What each code means: Form 4 transaction codes.
| Code | Meaning | Rows | Shares | Value |
|---|---|---|---|---|
| M | Option exercise or conversion | 6 | 20,276 | $523K |
| S | Open-market sale | 3 | 13,599 | $3.7M |
| A | Grant or award | 2 | 3,774 | — |
| Year | Rows | Bought | Sold |
|---|---|---|---|
| 2026 | 11 | 0 | 3 · $3.7M |
Transactions
| Security | Side | Trade date | Disclosed | Lag | Shares | Price | Value | Flags | Source | Share |
|---|---|---|---|---|---|---|---|---|---|---|
| LGND | Option / conversion M | August 12, 2026 | August 14, 2026 | 2d | 6,138 | — | — | derivative | Form 4 ↗ | |
| LGND | Sell S | August 12, 2026 | August 14, 2026 | 2d | 7,138 | $293 | $2.1M | Form 4 ↗ | ||
| LGND | Option / conversion M | August 12, 2026 | August 14, 2026 | 2d | 6,138 | $52 | $316K | Form 4 ↗ | ||
| LGND | Option / conversion M | June 12, 2026 | June 15, 2026 | 3d | 1,000 | — | — | derivative | Form 4 ↗ | |
| LGND | Option / conversion M | June 12, 2026 | June 15, 2026 | 3d | 3,000 | — | — | derivative | Form 4 ↗ | |
| LGND | Sell S | June 12, 2026 | June 15, 2026 | 3d | 3,461 | $256 | $886K | Form 4 ↗ | ||
| LGND | Sell S | June 12, 2026 | June 15, 2026 | 3d | 3,000 | $255 | $765K | Form 4 ↗ | ||
| LGND | Option / conversion M | June 12, 2026 | June 15, 2026 | 3d | 1,000 | $52 | $52K | Form 4 ↗ | ||
| LGND | Option / conversion M | June 12, 2026 | June 15, 2026 | 3d | 3,000 | $52 | $155K | Form 4 ↗ | ||
| LGND | Other A | June 5, 2026 | June 9, 2026 | 4d | 2,938 | — | — | derivative | Form 4 ↗ | |
| LGND | Other A | June 5, 2026 | June 9, 2026 | 4d | 836 | — | — | Form 4 ↗ |
Filings
| Filed | Form | Accession | Rows | Status | Source |
|---|---|---|---|---|---|
| August 14, 2026 | Form 4 | 0002001011-26-000114 | 3 | published | EDGAR ↗ |
| June 15, 2026 | Form 4 | 0002001011-26-000104 | 6 | published | EDGAR ↗ |
| June 9, 2026 | Form 4 | 0002001011-26-000097 | 2 | published | EDGAR ↗ |
Other insiders at LIGAND PHARMACEUTICALS INC
- Reardon Andrew CLO & Secretary 84 rows
- Espinoza Octavio Chief Financial Officer 56 rows
- KOZARICH JOHN W Director 49 rows
- LAMATTINA JOHN L Director 15 rows
- Davis Todd C Chief Executive Officer 13 rows
- Sabba Stephen L Director 9 rows
- Gray Nancy Ryan Director 8 rows
- Aryeh Jason Director 6 rows
- Zimmermann Martine Director 5 rows
Everyone on file, with contracts and lobbying under the company's name: LIGAND PHARMACEUTICALS INC.
Guides for this page
- What is SEC Form 4? Who files: officers, directors and owners of more than 10% of a class of the company's shares.
- Form 4 transaction codes P = purchase. S = sale. These are the two market trades.
- Insider buying vs insider selling Selling outweighs buying by a wide margin in normal times.
- Options and derivatives on Form 4 Table I = shares. Table II = options and other derivatives.
- What disclosure data cannot tell you Filings are late by design: up to 45 days for Congress, two business days for insiders.
Sources and method
| Source | Filings | Rows | First filed | Newest filed | Read the originals |
|---|---|---|---|---|---|
| SEC EDGAR, Form 4 | 3 | 11 | June 9, 2026 | August 14, 2026 | Form 4 list on EDGAR |
Site built October 27, 2026. Every row in the tables above links to its own filing. To quote a figure, use the Cite button at the top of the page; see how to cite and reuse.
Every row comes from the reporting owner's Form 4 as filed with the SEC (EDGAR ownership XML), read daily. "Value" is shares × the reported price; code P is an open-market purchase, S a sale, M an option exercise, A a grant. The lag is the filing date minus the trade date; Form 4 is due within two business days. Amendments (4/A) are not merged. Details on the methodology page; report an error on corrections.
Not investment advice. Figures are public disclosures shown as filed; they may lag the trade and may be amended later. No recommendation is made or implied.